Treatment with the SGLT2 inhibitor empagliflozin is associated with a reduction in myocardial extracellular volume among individuals with type 2 diabetes and coronary artery disease, suggests an analysis of data from the EMPA-HEART CardioLink-6 trial.
A review of data from the osimertinib clinical trials program has not identified a causal relationship between the use of the EGFR–tyrosine kinase inhibitor and cardiotoxicity among patients with advanced non-small-cell lung cancer.
A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.
UK research has identified a “strong dose-dependent” association between oral glucocorticoid use and CVD risk among people with immune-mediated diseases, with an increased risk seen even at doses of less than 5 mg/day.
The risk for cardiovascular disease is at least one-fifth higher in people with type 2 diabetes than in those without diabetes, even when risk factors are optimally controlled, study findings indicate.
The EMPATROPISM trial, which enrolled people without type 2 diabetes, shows reversal of left ventricular remodeling in patients with heart failure and reduced ejection fraction given empagliflozin rather than placebo.
A Spanish cross-sectional study suggests that a substantial proportion of people with type 2 diabetes are at very high risk for fatal cardiovascular events and could be considered as coronary artery disease equivalent.”
Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.
The risk for heart failure falls significantly with reductions in fat mass and waist circumference in overweight or obese people with type 2 diabetes, shows an analysis of data from the Look AHEAD trial.
Empagliflozin reduces the risk for adverse cardiovascular outcomes in people with heart failure and a reduced ejection fraction irrespective of their baseline glycated hemoglobin level, EMPEROR-Reduced trial data show.
Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.
Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.
Older patients and those with cardiovascular disease are most likely to have an increased risk for lower limb amputation when newly prescribed canagliflozin, relative to a GLP-1 receptor agonist, research shows.
A real-world comparison of biologic, targeted synthetic, and conventional DMARDs indicates that TNF inhibitors and abatacept are associated with a reduction in CVD risk in patients with rheumatoid arthritis.